Long‐term survival for 93 months of limited‐stage small cell lung cancer: A case report and literature review

Thoracic Cancer

Yujie Zhong¹  Qiuhong Zhang¹  Wenjing Deng¹  Yuping Zhang¹  Zongjuan Ming¹  Yanli Hou¹  Zequn Niu¹ 

[1]Department of Respiratory Medicine, the Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China

关键词: Chemotherapy;    long‐term survival;    prophylactic cranial irradiation;    radiotherapy;    small cell lung cancer;   

DOI  :  10.1111/1759-7714.12088

来源: Wiley

【 摘 要 】

Abstract

A 49-year-old man was diagnosed with small cell lung cancer in May 2005. Chemotherapy was started with 60 mg/day cisplatin iv drip (from days one to three), 2 mg topotecan (TP) hydrochloride iv drip (from days one to four), and traditional Chinese medicine (TCM) AiDi injection for anti-tumor. After four cycles, he underwent conformal radiotherapy with 56Gy/28 fractions in October 2005. In April 2006, a mass on the right supraclavicular area was found. Therefore, he underwent another course of radiotherapy. The fields included the right supraclavicular area and the radiation dose was 50Gy/25 fractions. After completion of chemoradiotherapy, the patient achieved complete remission. Subsequently, the patient received prophylactic cranial irradiation (PCI). Until April of 2012, he had been followed up regularly. Since the SCLC diagnosis, he had received TCM for seven years. In April 2012, the patient complained of coughing again. Subsequently, the patient was given five cycles of an etoposide carboplatin regimen. A computed tomography (CT) scan was performed for review, which showed no obvious change. The patient underwent a second-line chemotherapy irinotecan cisplatin three times. However, the symptoms and CT of this patient showed no significant improvement. We changed the chemotherapy regimen to TP (topotecan 1.2 mg iv drip, days one to five; carboplatin 100 mg iv drip, days one to five). After two TP regimens, the patient died in his sleep on 3 March 2013. In this case, the standardized sequential chemotherapy and radiotherapy treatment, PCI, TCM, and good compliance may have contributed to the patient's longer survival.

【 授权许可】

Unknown   
© 2014 Tianjin Lung Cancer Institute and Wiley Publishing Asia Pty Ltd